Davide Arillotta
Overview
Explore the profile of Davide Arillotta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
159
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maida N, Aquilina V, Vaiano F, Cavallo M, Locatelli C, Mannaioni G, et al.
J Anal Toxicol
. 2025 Mar;
PMID: 40088058
Synthetic cathinones (SCs) were confirmed as the second most prevalent class of NPS in 2024, underscoring their widespread availability and use. Notably, the SCs seizure and related intoxication cases increased...
2.
Dunn J, Schifano F, Dudley E, Arillotta D, Guirguis A
Brain Sci
. 2025 Feb;
15(2).
PMID: 40002505
Background/objectives: The misuse of veterinary drugs is a growing concern, with increasing evidence of their presence in illicit drug markets and their use as alternatives to traditional substances. Methods: This...
3.
Croce E, Dimitrova A, Di Milia M, Pierotti S, Arillotta D, Barbaresi M, et al.
J Anal Toxicol
. 2024 Nov;
49(2):137-141.
PMID: 39604091
The synthetic cathinone (SC) 3,4-methylenedioxy-α-pyrrolidinohexanophenone (MDPHP) is structurally correlated to the 3,4-methylenedioxypyrovalerone (MDPV). In recent years, the number of intoxication cases has increased even if little is known about the...
4.
Arillotta D, Floresta G, Papanti Pelletier G, Guirguis A, Corkery J, Martinotti G, et al.
Brain Sci
. 2024 Jun;
14(6).
PMID: 38928616
Glucagon-like peptide-1 (GLP-1) is involved in a range of central and peripheral pathways related to appetitive behavior. Hence, this study explored the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs)...
5.
Arillotta D, Totti A, Dimitrova A, Croce E, Di Milia M, Gambassi F, et al.
J Pharm Biomed Anal
. 2024 Jan;
241:115974.
PMID: 38277706
MDPHP is a synthetic cathinone (SC) belonging to α-pyrrolidinophenone derivatives. It is a central nervous system stimulant and may induce hallucinations, paranoia, tachycardia, hypertension, chest pain, and rhabdomyolysis. In literature,...
6.
Mullin A, Scott M, Vaccaro G, Floresta G, Arillotta D, Catalani V, et al.
Pharmacy (Basel)
. 2024 Jan;
12(1).
PMID: 38251407
Introduction: The designer benzodiazepine (DBZD) market continues to expand whilst evading regulatory controls. The widespread adoption of social media by pro-drug use communities encourages positive discussions around DBZD use/misuse, driving...
7.
Arillotta D, Floresta G, Guirguis A, Corkery J, Catalani V, Martinotti G, et al.
Brain Sci
. 2023 Nov;
13(11).
PMID: 38002464
The emergence of glucagon-like peptide-1 receptor agonists (GLP-1 RAs; semaglutide and others) now promises effective, non-invasive treatment of obesity for individuals with and without diabetes. Social media platforms' users started...
8.
Munafo A, Arillotta D, Mannaioni G, Schifano F, Bernardini R, Cantarella G
Pharmaceuticals (Basel)
. 2023 Jan;
16(1).
PMID: 36678564
Psilocybin has been suggested as a promising transdiagnostic treatment strategy for a wide range of psychiatric disorders. Recent findings showed that psychedelic-assisted/"psycholitic" psychotherapy should provide significant and sustained alleviation of...
9.
Schifano F, Catalani V, Sharif S, Napoletano F, Corkery J, Arillotta D, et al.
Drugs
. 2022 Apr;
82(7):839.
PMID: 35476318
No abstract available.
10.
Schifano F, Catalani V, Sharif S, Napoletano F, Corkery J, Arillotta D, et al.
Drugs
. 2022 Apr;
82(6):633-647.
PMID: 35366192
'Smart drugs' (also known as 'nootropics' and 'cognitive enhancers' [CEs]) are being used by healthy subjects (i.e. students and workers) typically to improve memory, attention, learning, executive functions and vigilance,...